| 7013- | Fuc, | Fucoidan-based nanoparticles for colorectal cancer therapy: Mechanisms and preclinical insights |
| - | Review, | CRC, | NA |
| 7014- | Fuc, | 5-FU, | Low-Molecular-Weight Fucoidan as Complementary Therapy of Fluoropyrimidine-Based Chemotherapy in Colorectal Cancer |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | Colon, | Caco-2 |
| 7015- | Fuc, | Effects of Ingesting Fucoidan Derived from Cladosiphon okamuranus Tokida on Human NK Cells: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Pilot Study |
| - | Trial, | Nor, | NA |
| 7016- | Fuc, | Therapies from Fucoidan: New Developments |
| - | Review, | Var, | NA |
| 7017- | Fuc, | Comparative study on neuroprotective activities of fucoidans from Fucus vesiculosus and Undaria pinnatifida |
| - | in-vitro, | AD, | PC12 |
| 7026- | Fuc, | Fucoidan |
| - | Review, | AD, | NA |
| 7018- | Fuc, | Absorption Study of Mozuku Fucoidan in Japanese Volunteers |
| - | Trial, | Nor, | NA |
| 7019- | Fuc, | Fucoidan protects hepatocytes from apoptosis and inhibits invasion of hepatocellular carcinoma by up-regulating p42/44 MAPK-dependent NDRG-1/CAP43 |
| - | vitro+vivo, | HCC, | HUH7 |
| 7020- | Fuc, | Systematic synthesis of low-molecular weight fucoidan derivatives and their effect on cancer cells |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Nor, | WI38 |
| 7025- | Fuc, | Pilot clinical study to evaluate the anticoagulant activity of fucoidan |
| - | Human, | Nor, | NA |
| 7024- | Fuc, | Fucoidan Alleviates Chemotherapy-Induced Peripheral Neuropathy via Activating the Gas6/MerTK Signaling Pathway to Reduce Neuroinflammation |
| 7023- | Fuc, | The Use of Oligo Fucoidan in Cancer Bearing Dogs Undergoing Chemotherapy: A Double-Blinded Study |
| - | Trial, | Var, | NA |
| 7022- | Fuc, | Antitumor Effects of Fucoidan on Human Colon Cancer Cells via Activation of Akt Signaling |
| - | in-vitro, | Colon, | HT29 |
| 7021- | Fuc, | Fucoidan Prevents the Progression of Osteoarthritis in Rats |
| - | in-vivo, | Arthritis, | NA |
| 7001- | Fuc, | Fucoidan reduces the toxicities of chemotherapy for patients with unresectable advanced or recurrent colorectal cancer |
| - | Trial, | CRC, | NA |
| 7000- | Fuc, | Efficacy of Low-Molecular-Weight Fucoidan as a Supplemental Therapy in Metastatic Colorectal Cancer Patients: A Double-Blind Randomized Controlled Trial |
| - | Trial, | CRC, | NA |
| 7009- | Fuc, | Effects of Fucoidan and Chemotherapeutic Agent Combinations on Malignant and Non-malignant Breast Cell Lines |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | Nor, | MCF12A |
| 6998- | Fuc, | Detection of Fucoidan in Urine after Oral Intake of Traditional Japanese Seaweed, Okinawa mozuku (Cladosiphon okamuranus Tokida) |
| - | Human, | Nor, | NA |
| 6999- | Fuc, | Fucoidan Improves Tumour Control and Liver Function in TACE for Unresectable Hepatocellular Carcinoma: A Randomised Trial |
| - | Trial, | HCC, | NA |
| - | Trial, | CRC, | NA |
| 7003- | Fuc, | Chemo, | An Exploratory Study on the Anti-inflammatory Effects of Fucoidan in Relation to Quality of Life in Advanced Cancer Patients |
| 7004- | Fuc, | Effectiveness of Fucoidan on Supplemental Therapy in Cancer Patients: A Systematic Review |
| - | Review, | Var, | NA |
| 7005- | Fuc, | Fucoidan and cancer: a multifunctional molecule with anti-tumor potential |
| - | Review, | Var, | NA |
| 7006- | Fuc, | Seaweeds in the Oncology Arena: Anti-Cancer Potential of Fucoidan as a Drug—A Review |
| - | Review, | Var, | NA |
| 7007- | Fuc, | The Therapeutic Potential of the Anticancer Activity of Fucoidan: Current Advances and Hurdles |
| - | Review, | Var, | NA |
| 7008- | Fuc, | Ten Years of Research on Fucoidan and Cancer: Focus on Its Antiangiogenic and Antimetastatic Effects |
| - | Review, | Var, | NA |
| - | in-vitro, | Oral, | NA |
| 4022- | FulvicA, | Chemo, | Shilajit potentiates the effect of chemotherapeutic drugs and mitigates metastasis induced liver and kidney damages in osteosarcoma rats |
| - | in-vivo, | OS, | NA |
| 4024- | FulvicA, | ANTI-CARCINOGENIC ACTIVITY OF SHILAJIT REGARDING TO APOPTOSIS ASSAY IN CANCER CELLS: A SYSTEMATIC REVIEW OF IN-VITRO STUDIES |
| - | Review, | Var, | NA |
| 4025- | FulvicA, | Mumio (Shilajit) as a potential chemotherapeutic for the urinary bladder cancer treatment |
| - | in-vitro, | Bladder, | T24/HTB-9 | - | Review, | AD, | NA |
| 4026- | FulvicA, | Shilajitin Cancer Treatment: Probable Mode of Action |
| - | Review, | Var, | NA |
| 4027- | FulvicA, | Mummy Induces Apoptosis Through Inhibiting of Epithelial-Mesenchymal Transition (EMT) in Human Breast Cancer Cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | Nor, | MCF10 |
| 4028- | FulvicA, | Mineral pitch induces apoptosis and inhibits proliferation via modulating reactive oxygen species in hepatic cancer cells |
| - | in-vitro, | Liver, | HUH7 |
| 4029- | FulvicA, | Chemo, | Shilajit mitigates chemotherapeutic drug-induced testicular toxicity: Study on testicular germ cell dynamics, steroidogenesis modulation, and Nrf-2/Keap-1 signaling |
| - | in-vivo, | Var, | NA |
| 4030- | FulvicA, | Therapeutic Potential of Fulvic Acid in Chronic Inflammatory Diseases and Diabetes |
| - | Review, | NA, | NA |
| 4018- | FulvicA, | Fe, | Inhibitory Impacts of Fulvic Acid-Coated Iron Oxide Nanoparticles on the Amyloid Fibril Aggregations |
| - | in-vivo, | AD, | NA |
| 4017- | FulvicA, | Fulvic acid inhibits aggregation and promotes disassembly of tau fibrils associated with Alzheimer's disease |
| - | NA, | AD, | NA |
| 4019- | FulvicA, | Can nutraceuticals prevent Alzheimer's disease? Potential therapeutic role of a formulation containing shilajit and complex B vitamins |
| - | Review, | AD, | NA |
| 4016- | FulvicA, | Shilajit: A Natural Phytocomplex with Potential Procognitive Activity |
| - | Review, | AD, | NA |
| 4020- | FulvicA, | Natural products as a rich source of tau-targeting drugs for Alzheimer’s disease |
| - | in-vitro, | AD, | NA |
| 4021- | FulvicA, | Scaling the Andean Shilajit: A Novel Neuroprotective Agent for Alzheimer’s Disease |
| - | in-vitro, | AD, | NA |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 |
| 7041- | GA, | Gallic acid suppresses the progression of clear cell renal cell carcinoma through inducing autophagy via the PI3K/Akt/Atg16L1 signaling pathway |
| - | vitro+vivo, | RCC, | 786-O | - | in-vitro, | RCC, | ACHN | - | in-vitro, | Nor, | HK-2 |
| 7035- | GA, | Gallic acid attenuates LPS-induced inflammation in Caco-2 cells by suppressing the activation of the NF-κB/MAPK signaling pathway |
| - | in-vitro, | IBD, | Caco-2 |
| 7037- | GA, | Chit, | Gallic acid-loaded chitosan nanoparticles enhance the DNA damage and apoptotic features through inhibiting flap endonuclease-1 in triple-negative breast cancer cells |
| - | in-vitro, | BC, | MDA-MB-231 |
| 7038- | GA, | Gallic acid for cancer therapy: Molecular mechanisms and boosting efficacy by nanoscopical delivery |
| - | Review, | Var, | NA |
| 7040- | GA, | Effects of gallic acid on acrylamide-induced endoplasmic reticulum stress, neuroinflammation and neuronal apoptosis in rats |
| - | Trial, | AD, | NA |
| 7042- | GA, | Gallic acid reduces cell growth by induction of apoptosis and reduction of IL-8 in HepG2 cells |
| - | in-vitro, | Liver, | HepG2 |
| 7043- | GA, | Gallic acid-induced lung cancer cell death is related to glutathione depletion as well as reactive oxygen species increase |
| - | in-vitro, | Lung, | Calu-1 | - | in-vitro, | Lung, | A549 |
| 7044- | GA, | QC, | Inhibitory effects of gallic acid and quercetin on UDP-glucose dehydrogenase activity |
| - | in-vitro, | BC, | MCF7 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid